Ulcavis tablets p/o 120mg №14×8

Name:
Ulcavis tab. captivity vol. 120mg in bl. in pack. No. 14×8
Description:
Round, slightly biconvex film-coated tablets of white or almost white color, with a bevel. Fractured appearance: rough mass of white color with a shell of white or almost white color. The main active ingredient is bismuth tripotassium dicitrate Release formtablets DosageFor adults and children over 12 years of age, Ulcavis® is prescribed 1 tablet 4 times a day 30 minutes before meals and at night or 2 tablets 2 times a day 30 minutes before meals. For children from 6 to 12 years old, Ulcavis® is prescribed at a dose of 8 mg / kg / day Special instructions Ulcavis® should not be used for more than 8 weeks. It is also not recommended during treatment to exceed the established daily doses for adults and children. During the period of treatment with Ulcavis®, other drugs containing bismuth should not be used. At the end of the course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 μg / l, and intoxication is observed only at a concentration in the blood plasma above 100 μg / l. When using the drug Ulcavis, it is possible to stain the feces in a dark color due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue. Pharmacological action: antiulcer, antihelicobacter, gastroprotective. Pharmacodynamics Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent properties. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, chelate compounds with a protein substrate are formed in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of PGE, the formation of mucus and the secretion of bicarbonate, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the area of the defect. Reduces the activity of pepsin. Pharmacokinetics Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. It is excreted mainly through the intestines with feces. A small amount of bismuth that enters the blood plasma is excreted from the body by the kidneys. Indications for use gastric ulcer and duodenal ulcer in the acute phase, incl. associated with Helicobacter pylori; chronic gastritis and gastroduodenitis in the acute phase, incl. associated with Helicobacter pylori; irritable bowel syndrome, occurring mainly with symptoms of diarrhea; functional dyspepsia, not associated with organic diseases of the gastrointestinal tract. Dosage and administration Inside, 30 minutes before meals, with a small amount of water. For adults and children over 12 years of age, Ulcavis® is prescribed 1 tablet. 4 times a day 30 minutes before meals and at night or 2 tablets. 2 times a day. For children from 8 to 12 years old, Ulcavis® is prescribed 1 tab. 2 times a day; from 4 to 8 years old is prescribed at a dose of 8 mg / kg / day, depending on the body weight of the child, 1-2 tablets / day (respectively, 1-2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). The duration of the course of treatment is 4-8 weeks. For the next 8 weeks, drugs containing bismuth should not be used. For the eradication of Helicobacter pylori, it is advisable to use Ulcavis® in combination with other antibacterial agents with anti-Helicobacter pylori activity (as recommended by a doctor). Use during pregnancy and lactationUse of the drug Ulcavis during pregnancy and during breastfeeding is contraindicated. Precautions Do not use Ulcavis® for more than 8 weeks. It is also not recommended during treatment to exceed the established daily doses for adults and children. During the period of treatment with Ulcavis®, other drugs containing bismuth should not be used. At the end of the course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 μg / l, and intoxication is observed only at a concentration in the blood plasma above 100 μg / l. Interaction with other drugsFor half an hour before and after taking the drug Ulcavis, it is not recommended to use other drugs orally, as well as the intake of food and liquids, in particular, antacids, milk, fruits and fruit juices. This is due to the fact that they, when taken orally, can affect the effectiveness of Ulcavis®. Simultaneous use of the drug Ulcavis® with tetracycline reduces the absorption of the latter. Contraindications: individual intolerance to the drug; severe renal failure (Cl creatinine less than 30 ml / min); pregnancy; breastfeeding; children under 4 years of age. Composition 1 tab. bismuth tripotassium dicitrate 303.03 mg, which corresponds to the content of bismuth oxide 120 mg The composition of the film shell: Opadry II transparent – 8.5 mg (polyvinyl alcohol – 4.505 mg, macrogol 4000 – 2.295 mg, talc – 1.7 mg), titanium dioxide (E171) – 1.5 mg. 10 pieces. – blisters (3) – packs of cardboard. 10 pieces. – blisters (4) – packs of cardboard. 10 pieces. – blisters (6) – packs of cardboard. 10 pieces. – blisters (10) – packs of cardboard. 10 pieces. – blisters (24) – packs of cardboard. 14 pcs. – blisters (2) – packs of cardboard. 14 pcs. – blisters (4) – packs of cardboard. 14 pcs. – blisters (8) – packs of cardboard. 14 pcs. – blisters (16) – packs of cardboard. 15 pcs. – blisters (2) – packs of cardboard. 15 pcs. – blisters (4) – packs of cardboard. 15 pcs. – blisters (8) – packs of cardboard. 15 pcs. – blisters (16) – packs of cardboard. Overdose Symptoms: dyspepsia, skin rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums. An overdose of Ulcavis caused by long-term use of doses higher than recommended may lead to impaired renal function. These symptoms are completely reversible when Ulcavis® is discontinued. Treatment: gastric lavage, administration of activated charcoal and saline laxatives. Further treatment should be symptomatic. In case of impaired renal function, which is accompanied by a high concentration of bismuth in the blood plasma, chelating agents (penicillamine, sodium dimercaptopropanesulfonate) can be prescribed. In case of severe renal impairment, hemodialysis is indicated. Side effect On the part of the digestive system: nausea, vomiting, more frequent stools, constipation may occur. These phenomena are not dangerous to health and are temporary. Allergic reactions: skin rash, pruritus. With prolonged use in high doses, the development of encephalopathy associated with the accumulation of bismuth in the central nervous system is possible. Storage conditionsAt a temperature not exceeding 25 °C, in original packaging Buy Ulcavis tablets p/o 120mg No. 14×8